The news is directly related to Anika Therapeutics (ANIK) as the analyst from Stephens & Co. reiterates an Equal-Weight rating and maintains a $28 price target. This reaffirmation of the rating and price target indicates that the analyst's view on the stock has not changed, and therefore, the short-term impact on the stock price is expected to be neutral.